Suppr超能文献

口服产肠毒素大肠杆菌疫苗的进展

Developments in oral enterotoxigenic Escherichia coli vaccines.

作者信息

Svennerholm Ann-Mari, Lundgren Anna

机构信息

Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden.

Dept. of Microbiology and Immunology, Inst. of Biomedicine, University of Gothenburg, Sweden.

出版信息

Curr Opin Immunol. 2023 Oct;84:102372. doi: 10.1016/j.coi.2023.102372. Epub 2023 Jul 29.

Abstract

Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea in children in developing countries and in travelers. WHO has affirmed ETEC as a priority vaccine target, but there is no licensed ETEC vaccine available yet. We here describe recent, promising developments of different live, inactivated, and subunit ETEC candidate vaccines expressing or containing nontoxic enterotoxin and/or colonization factor antigens with a focus on oral vaccines. Many of the ETEC candidate vaccines have been tested in clinical trials for safety and immunogenicity and some of them also for protective efficacy in field trials or in challenge studies.

摘要

产肠毒素大肠杆菌(ETEC)是发展中国家儿童及旅行者腹泻的主要病因。世界卫生组织已认定ETEC为优先疫苗研发目标,但目前尚无已获许可的ETEC疫苗。我们在此描述不同类型的活疫苗、灭活疫苗和亚单位ETEC候选疫苗的近期进展,这些疫苗表达或包含无毒肠毒素和/或定植因子抗原,重点介绍口服疫苗。许多ETEC候选疫苗已在临床试验中进行了安全性和免疫原性测试,其中一些还在现场试验或攻毒研究中进行了保护效力测试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验